Rhumbline Advisers Decreases Stake in Inogen, Inc $INGN

Rhumbline Advisers lowered its holdings in Inogen, Inc (NASDAQ:INGN) by 5.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,498 shares of the medical technology company’s stock after selling 2,085 shares during the quarter. Rhumbline Advisers owned 0.14% of Inogen worth $260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of INGN. Strs Ohio purchased a new position in shares of Inogen during the first quarter valued at approximately $468,000. Acadian Asset Management LLC raised its stake in Inogen by 35.7% during the 1st quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company’s stock valued at $7,325,000 after buying an additional 270,453 shares during the last quarter. Jane Street Group LLC purchased a new stake in Inogen during the 1st quarter valued at $463,000. Goldman Sachs Group Inc. raised its stake in Inogen by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company’s stock valued at $2,026,000 after buying an additional 41,002 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Inogen during the 1st quarter valued at $85,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Trading Up 0.4%

Inogen stock opened at $8.46 on Friday. The firm has a 50 day moving average of $7.55 and a 200 day moving average of $7.10. The firm has a market capitalization of $228.76 million, a price-to-earnings ratio of -7.98 and a beta of 1.78. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $12.91.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%.The business had revenue of $92.28 million during the quarter, compared to analyst estimates of $90.40 million. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts predict that Inogen, Inc will post -1.73 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, B. Riley assumed coverage on Inogen in a research report on Monday, June 16th. They set a “buy” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Inogen has an average rating of “Moderate Buy” and an average price target of $11.00.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.